Targeting PIASxα and SENP2 to alter the SUMOylation of 5-HT1ARs could have important clinical relevance for the therapeutic intervention for anxiety disorders, as well as other neuropsychiatric disorders in which 5-HT1ARs are implicated. The gene discussed is SENP2; the disease is anxiety disorder.